Research and Markets Announces Addition of the "Risk - Reward of Developing a Herceptin Biosimilar - A Thorough Assessment" Report to its Offering

• 

Dublin, Ireland (PRWEB) February 28, 2013

Herceptin exclusivity is expiring in major geographies and many Biosimilar players (both experienced and new entrant) are looking to have a share of this potential $6billion pie. Herceptin sales are critical to Roche as it comprise about 15% of its cumulative Pharma sales. While eying for this potential lucrative opportunity, there are several risks and barriers that Biosimilar players should be aware. The report – “Risk – Reward of Developing a Herceptin biosimilar – A thorough assessment” looks into several aspects of potential opportunity size for Biosimilar players, with regard to:

• European Experience of Biosimilars
• Current market positioning of Herceptin across geography
• Different technologies deployed by biosimilar players
• Competition – Pipeline of Biosimilar and Biobetters targeting Herceptin
• Potential Market Expansion post expiry of Market Exclusivity
• Defense Strategies deployed by Roche
• Ongoing Clinical trials and their impact on Market Opportunity
• Global Regulatory Process and Hurdles
• Risk/Reward profile of developing Herceptin biosimilar

For more information visit http://www.researchandmarkets.com/research/8p8bc7/risk_reward_of

Research and Markets
Laura Wood, Senior Manager.
Email: press(at)researchandmarkets(dot)com
Phone: +35314151241

Sector: Biotechnology

PDF Print